Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Nov 15, 2025; 17(11): 109375
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.109375
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.109375
Table 1 Baseline characteristics of participants, n (%)
| Parameters | Sevoflurane group (n = 103) | Propofol group (n = 101) | t/χ2 | P value |
| Age (years) | 59.72 ± 9.79 | 60.21 ± 10.13 | 0.349 | 0.728 |
| Sex | 0.245 | 0.621 | ||
| Male | 67 (65.05) | 69 (68.32) | ||
| Female | 36 (34.95) | 32 (31.68) | ||
| BMI (kg/m2) | 23.79 ± 2.25 | 24.10 ± 2.53 | 0.910 | 0.364 |
| ECOG | 0.003 | 0.954 | ||
| 0 | 88 (85.44) | 86 (85.15) | ||
| 1 | 15 (14.56) | 15 (14.85) | ||
| ASA classification | 0.420 | 0.811 | ||
| I | 44 (42.72) | 41 (40.59) | ||
| II | 58 (56.31) | 58 (57.43) | ||
| III | 1 (0.97) | 2 (1.98) | ||
| Systolic blood pressure (mmHg) | 115.01 ± 11.62 | 114.09 ± 11.28 | 0.572 | 0.568 |
| Diastolic blood pressure (mmHg) | 75.33 ± 10.12 | 72.70 ± 11.01 | 1.778 | 0.077 |
| Heart rate (bpm) | 129.78 ± 24.25 | 135.41 ± 25.30 | 1.622 | 0.106 |
| Hemoglobin (g/dL) | 12.98 ± 1.28 | 13.10 ± 1.33 | 0.659 | 0.510 |
| Underlying diseases | ||||
| Hypertension | 79 (76.70) | 71 (70.30) | 1.074 | 0.300 |
| Diabetes | 37 (35.92) | 46 (54.46) | 1.956 | 0.162 |
Table 2 Intraoperative indicators comparison
| Parameters | Sevoflurane group (n = 103) | Propofol group (n = 101) | t | P value |
| Total anesthesia time (minute) | 181.54 ± 29.23 | 174.95 ± 26.33 | 1.691 | 0.092 |
| Total operation time (minute) | 161.85 ± 19.12 | 158.25 ± 17.13 | 1.416 | 0.158 |
| Bleeding (mL) | 106.95 ± 52.12 | 116.18 ± 52.33 | 1.263 | 0.208 |
| Urine (mL) | 757.98 ± 299.85 | 762.11 ± 312.31 | 0.096 | 0.923 |
Table 3 Comparison of clinical outcomes at 30 days post-surgery, n (%)
| Parameters | Sevoflurane group (n = 103) | Propofol group (n = 101) | t/χ2 | P value |
| In-hospital mortality | 0 (0) | 2 (1.98) | 0.525 | 0.469 |
| Length of hospital stay, day | 7.58 ± 1.12 | 7.39 ± 0.98 | 1.282 | 0.201 |
| Emergency department visit | 22 (21.36) | 28 (27.72) | 1.116 | 0.291 |
| Readmission rate | 4 (3.88) | 8 (7.92) | 1.501 | 0.220 |
Table 4 Intraoperative hemodynamics
| Parameters | Sevoflurane group (n = 103) | Propofol group (n = 101) | t | P value |
| At the time of incision | ||||
| Systolic blood pressure (mmHg) | 114.21 ± 12.09 | 118.02 ± 14.12 | 2.074 | 0.039 |
| Diastolic blood pressure (mmHg) | 70.68 ± 10.84 | 74.50 ± 11.90 | 2.401 | 0.017 |
| Heart rate (bpm) | 121.52 ± 17.24 | 123.81 ± 16.70 | 0.963 | 0.337 |
| At the time of gastrectomy | ||||
| Systolic blood pressure (mmHg) | 111.28 ± 11.71 | 112.35 ± 11.50 | 0.661 | 0.509 |
| Diastolic blood pressure (mmHg) | 69.54 ± 9.84 | 71.27 ± 9.35 | 1.282 | 0.201 |
| Heart rate (bpm) | 116.82 ± 12.33 | 120.89 ± 15.97 | 2.038 | 0.043 |
| At the time of skin suturing | ||||
| Systolic blood pressure (mmHg) | 108.90 ± 14.02 | 108.91 ± 13.17 | 0.003 | 0.998 |
| Diastolic blood pressure (mmHg) | 69.71 ± 11.65 | 70.61 ± 12.18 | 0.541 | 0.589 |
| Heart rate (bpm) | 119.03 ± 13.04 | 123.05 ± 14.83 | 2.055 | 0.041 |
| At the end of the surgery | ||||
| Systolic blood pressure (mmHg) | 102.82 ± 13.21 | 105.70 ± 13.74 | 1.522 | 0.129 |
| Diastolic blood pressure (mmHg) | 66.35 ± 10.53 | 67.08 ± 10.64 | 0.494 | 0.622 |
| Heart rate (bpm) | 119.89 ± 12.64 | 123.64 ± 14.35 | 1.984 | 0.049 |
Table 5 Intraoperative and postoperative adverse events, n (%)
| Parameters | Sevoflurane group (n = 103) | Propofol group (n = 101) | χ2 | P value |
| Intraoperative | ||||
| Body movement | 24 (23.3) | 34 (33.66) | 2.691 | 0.101 |
| Hypoxia | 3 (2.91) | 6 (5.94) | 0.507 | 0.476 |
| Postoperative | ||||
| Hypoxia | 3 (2.91) | 0 (0) | 1.314 | 0.252 |
| Agitation | 8 (7.77) | 8 (7.92) | 0.002 | 0.967 |
| Nausea | 29 (28.16) | 45 (44.55) | 5.933 | 0.015 |
| Vomiting | 12 (11.65) | 14 (13.86) | 0.224 | 0.636 |
| Pruritus | 14 (13.59) | 17 (13.59) | 0.415 | 0.519 |
| Hypotensive episode | 24 (23.3) | 14 (13.86) | 2.998 | 0.083 |
Table 6 Postoperative complications, n (%)
| Parameters | Sevoflurane group (n = 103) | Propofol group (n = 101) | t/χ2 | P value |
| Patients with no complications | 35 (33.98) | 42 (41.58) | 1.255 | 0.263 |
| Clavien-Dindo classification of complication severity | 1.965 | 0.854 | ||
| I | 12 (11.65) | 8 (7.92) | ||
| II | 42 (40.78) | 36 (35.64) | ||
| IIIa | 28 (27.18) | 33 (32.67) | ||
| IVa | 8 (7.77) | 10 (9.9) | ||
| IVb | 5 (4.85) | 6 (5.94) | ||
| V | 8 (7.77) | 8 (7.92) | ||
| CCI of complication severity | 19.85 ± 2.50 | 20.40 ± 2.55 | 1.550 | 0.123 |
Table 7 Visual Analog Scale scores
| Parameters | Sevoflurane group (n = 103) | Propofol group (n = 101) | t | P value |
| Postoperative 2 hours | 24.35 ± 7.79 | 25.16 ± 7.52 | 0.761 | 0.447 |
| Postoperative 4 hours | 22.54 ± 6.58 | 23.61 ± 6.77 | 1.141 | 0.255 |
| Postoperative 6 hours | 21.51 ± 6.17 | 22.92 ± 6.05 | 1.650 | 0.101 |
| Postoperative 24 hours | 22.93 ± 6.13 | 24.61 ± 6.02 | 1.977 | 0.049 |
| Postoperative 48 hours | 24.52 ± 8.17 | 24.70 ± 8.12 | 0.152 | 0.880 |
- Citation: Wang Z, Cheng JW, Yu KY. Short-term and long-term effects of sevoflurane inhalation vs propofol total intravenous anesthesia in gastrectomy for gastric cancer. World J Gastrointest Oncol 2025; 17(11): 109375
- URL: https://www.wjgnet.com/1948-5204/full/v17/i11/109375.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i11.109375
